Yaara Ofir-Rosenfeld

Author

Mission Therapeutics (United Kingdom)ORCID

Also Known As

Y. Ofir-Rosenfeld, Yaara Ofir-Rosenfeld

106

Publications

629

Citations

H-Index

Concepts

All Affiliations

Mission Therapeutics (United Kingdom)Charles River Laboratories (United Kingdom)Hutchison/MRC Research Centre University of Cambridge Weizmann Institute of Science

About

Yaara Ofir-Rosenfeld is an author at Mission Therapeutics (United Kingdom) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	384
2	Cell Biology	4	4	384
3	Immunology	2	2	54
4	Engineering	1	1	100
5	Natural Sciences	1	1	230

Yaara Ofir-Rosenfeld

Publications

611

Citations

H-Index

Page 1

	Year	Citations
Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26 Yaara Ofir-Rosenfeld, Kristy Boggs, Dan Michael, Molecular Cell MedicineNatural SciencesMolecular BiologyInhibitory InteractionsTumor Suppressor	2008	230
The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1 Yael Aylon, Yaara Ofir-Rosenfeld, Norikazu Yabuta, Genes & Development	2010	102
A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization Anand D. Jeyasekharan, Yang Liu, Hiroyoshi Hattori, Nature Structural & Molecular Biology ChromatinGenome InstabilityEngineeringMedicineCancer Cell Biology	2013	100
Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic, Cancer Discovery	2023	100
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade Yaara Ofir-Rosenfeld, L. Vasiliauskaitė, C. Saunders, European Journal of Cancer Cancer ImmunosurveillanceTumour GrowthImmunologyTumor ImmunityRna Methyltransferase Mettl3	2022	27
Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies. Justin C. Moser, Kyriakos P. Papadopoulos, Jordi Rodón, Journal of Clinical Oncology Cancer ManagementImmunologyCancer InitiationPharmacotherapyImmunotherapeutics	2024	27
Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia Konstantinos Tzelepis, Étienne De Braekeleer, Eliza Yankova, Blood	2019	25

Page 1